Selective immune cell removal may tame transplant complications
NCT ID NCT02220985
First seen Jun 08, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemotherapy and radiation before transplant. The goal was to reduce GVHD while keeping the donor cells' ability to fight infections and cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Allogeneic hematopoietic stem cell transplantation with selective depletion of CD45RA+ T cells
What this could lead to
If successful, this approach could reduce the severity of graft-versus-host disease while preserving the donor cells' ability to fight infections and cancer, improving outcomes for stem cell transplant recipients.
What could go wrong
This is a phase II trial with a moderate number of participants, so results may not be definitive. The procedure is complex and carries risks such as graft failure, infection, or relapse of the underlying cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.